22934-59-4

Basic information

• Product Name: 7-METHOXY-1,3-BENZODIOXIDE-5-METHANOL
• Synonyms: RARECHEM AL BD 1486;7-METHOXY-1,3-BENZODIOXIDE-5-METHANOL;7-METHOXY-1,3-BENZODIOXIDE-5-MATHANOL;(7-methoxybenzo[d][1,3]dioxol-5-yl)methanol
• CAS NO: 22934-59-4
• Molecular Formula: C₉H₁₀O₄
• Molecular Weight: 182.17
• Mol File: 22934-59-4.mol
• Article Data: 20

Chemical Properties

• Boiling Point: 315.7°Cat760mmHg
• Flash Point: 144.7°C
• Appearance: /
• Density: 1.315g/cm³
• Vapor Pressure: 0.000182mmHg at 25°C
• Refractive Index: 1.571
• CAS DataBase Reference: 7-METHOXY-1,3-BENZODIOXIDE-5-METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: 7-METHOXY-1,3-BENZODIOXIDE-5-METHANOL(22934-59-4)
• EPA Substance Registry System: 7-METHOXY-1,3-BENZODIOXIDE-5-METHANOL(22934-59-4)

Safety Data

• Hazardous Substances Data: 22934-59-4(Hazardous Substances Data)

Usage

InChI:InChI=1/C9H10O4/c1-11-7-2-6(4-10)3-8-9(7)13-5-12-8/h2-3,10H,4-5H2,1H3

Upstream product

• 116119-01-8 methyl 7-hydroxybenzo[d][1,3]dioxole-5-carboxylate 
• 3934-87-0 5-hydroxyvanillin 
• 2973-76-4 5-bromo-4-hydroxy-3-methoxybenzaldehyde 
• 121-33-5 vanillin 
• 487-62-7 isomyristicin 
• 607-91-0 myristicin 
• 81474-46-6 4-bromo-7-methoxybenzo[1,3]dioxole-5-carboxylic acid methyl ester 
• 22934-58-3 methyl 7-methoxybenzo[d][1,3]dioxole-5-carboxylate 
• 3934-84-7 3,4-dihydroxy-5-methoxybenzoic acid 
• 149-91-7 3,4,5-trihydroxybenzoic acid 
• 108853-29-8 n-butyl 3,4-dihydroxy-5-methoxybenzoate 
• 1083-41-6 n-butyl gallate 
• 3934-86-9 methyl 3,4-dihydroxy-5-methoxybenzoate 
• 99-24-1 methyl galloate 

Downstream Products

• 1276358-64-5 3-(4-methoxyphenyl)-3-oxo-2-(3-methoxy-4,5-methylenedioxyphenyl)propanenitrile 
• 1301751-70-1 5-(4-methoxyphenyl)-4-(3-methoxy-4,5-methylenedioxyphenyl)-1H-pyrazol-3-amine 
• 5780-07-4 3-methoxy-4,5-methylenedioxybenzaldehyde 
• 111394-53-7 3'-hydroxy-3,4-methylenedioxy-4',5-dimethoxy-(E)-stilbene 
• 111394-44-6 3'-hydroxy-4,5-methylenedioxy-3,4'-dimethoxy-(Z)-stilbene 
• 111394-50-4 combretastatin A-2 3'-O-p-bromophenylcarbamate 
• 111394-47-9 combretastatin A-2 acetate 
• 111394-49-1 combretastatin B-1 
• 96909-18-1 (+/-)-Demethoxymegaphyllone acetate 
• 96909-07-8 3-(7-Methoxy-benzo[1,3]dioxol-5-yl)-2-methyl-oxirane-2-carboxylic acid methyl ester 
• 101751-71-7 (-)-cubebinone 
• 119138-77-1 2R,3R,2-(7-methoxy 1,3-benzodioxol-5-yl) methyl 3-(3,4,5-trimethoxyphenyl) methyl butan-1,4-diol 

Relevant articles and documents

Asymmetric total synthesis of four bioactive lignans using donor-acceptor cyclopropanes and bioassay of (?)- and (+)-niranthin against hepatitis B and influenza viruses

The asymmetric total synthesis of four lignans, dimethylmatairesinol, matairesinol, (?)-niranthin, and (+)-niranthin has been achieved using reductive ring-opening of cyclopropanes. Moreover, we performed bioassays of the synthesized (+)- and (?)-niranthins using hepatitis B and influenza viruses, which revealed the relationship between the enantiomeric structure and the anti-viral activity of niranthin.

Methanol as hydrogen source: Transfer hydrogenation of aromatic aldehydes with a rhodacycle

A cyclometalated rhodium complex has been shown to perform highly selective and efficient reduction of aldehydes, deriving the hydrogen from methanol. With methanol as both the solvent and hydrogen donor under mild conditions and an open atmosphere, a wide range of aromatic aldehydes were reduced to the corresponding alcohols, without affecting other functional groups.

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.